# Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

> **NCT01933932** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 510 (actual)

## Conditions studied

- Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

## Interventions

- **DRUG:** Selumetinib
- **DRUG:** Docetaxel
- **DRUG:** Placebo
- **DRUG:** Pegylated G-CSF

## Key facts

- **NCT ID:** NCT01933932
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-09-25
- **Primary completion:** 2016-06-07
- **Final completion:** 2025-12-31
- **Target enrollment:** 510 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01933932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01933932, "Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01933932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*